25 citations
,
November 2013 in “Journal of the American Academy of Dermatology” This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.
April 2026 in “World Allergy Organization Journal” This study found that allergic rhinitis is linked to a higher risk of developing androgenetic alopecia, while second-generation H1-antihistamine use was associated with a reduced risk, especially in younger patients.
3 citations
,
January 2024 in “Innovaciencia Facultad de Ciencias Exactas Físicas y Naturales” This review outlines the development and clinical use of three generations of antihistamines, noting that while first-generation drugs have multiple side effects including sedation, second- and third-generation antihistamines offer greater efficacy and safety due to their selective action on peripheral H1 receptors.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
October 2025 in “Archives of Clinical Toxicology” This commentary highlights that cetirizine, a widely-used antihistamine, remains effective for various emerging allergic conditions, and new formulations and combination therapies may enhance its effectiveness while being generally well-tolerated.
